‹ Moderna
Ch 5 · The Story Behind the Numbers
Chapter 5 · Behind the Numbers
The numbers, in the company's own words.
Every filing has a section where management explains what just happened — and why. Here's Moderna's.
↓ scroll to read
✦ The bottom line
Anyone can read the revenue line. The story — why it fell, where the cash is going, and which pipeline bet matters most — is the part Moderna writes itself. Here are the threads that matter.
↓ the brief below
✦ Five threads from Moderna's filings
1
The base is now COVID + RSV.
Current revenue comes from Spikevax/mNEXSPIKE (COVID) and mRESVIA (RSV) — seasonal respiratory vaccines, far smaller than the boom. This is the new, normalized base the company grows from.
2
The big swing is a cancer vaccine.
Moderna and Merck reported multi-year Phase 2b data for intismeran autogene (mRNA-4157), an individualized cancer vaccine used with Merck's Keytruda, showing sustained improvement in keeping melanoma from recurring. If it succeeds in late-stage trials, it would be the platform's biggest validation beyond infectious disease.
3
Spending is being pulled back — but it's still huge.
Management has announced cost reductions to extend the runway, but R&D remains in the billions. The tension is constant: cut enough to preserve the war chest, but not so much that you starve the pipeline that justifies the company.
4
The cash cushion is the lifeline.
Moderna funds its losses from reserves accumulated during COVID, not from new fundraising. Watching that balance shrink quarter to quarter is the clearest gauge of how much time the platform bet has.
5
The pipeline is broad — for better and worse.
Beyond cancer and RSV, Moderna is pursuing flu, combination respiratory vaccines, and rare diseases. Breadth means more shots on goal, but also more spending — and the risk of doing many things adequately instead of a few exceptionally.
Source · 10-K · MD&A + Business · FY2025 · Filed Feb 20, 2026
●
Read the whole story
Five threads: a COVID+RSV base, a make-or-break cancer-vaccine bet with Merck, cost cuts, a shrinking cash cushion, and a broad (maybe too broad) pipeline.
You just finished
Chapter 5 · BEHIND THE NUMBERS
The Story Behind the Numbers
you now read: reading the MD&A
Up next